Developing an outcome measure with high luminance for optogenetics treatment of severe retinal degenerations and for gene therapy of cone diseases Academic Article uri icon

Overview

MeSH Major

  • Color Vision
  • Color Vision Defects
  • Genetic Therapy
  • Light
  • Optogenetics
  • Retinal Cone Photoreceptor Cells
  • Retinal Degeneration

abstract

  • The modified MP1 can be developed into an outcome measure for treatments in patients with severe retinal degeneration, very low vision, and abnormal eye movements such as those for whom treatment with optogenetics is planned, as well as for patients with cone disorders such as blue cone monochromacy for whom treatment with gene therapy is planned to improve L/M-cone function above a normal complement of rod and S-cone function.

publication date

  • June 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4928698

Digital Object Identifier (DOI)

  • 10.1167/iovs.16-19586

PubMed ID

  • 27309625

Additional Document Info

start page

  • 3211

end page

  • 21

volume

  • 57

number

  • 7